About Synaptotagmin-7
Synaptotagmin-7 (SYT7) is a protein
from Homo sapiens identified by UniProt accession
O43581, 403 residues long.
MolForge cross-references it against 0 known binders and
77 disease associations.
Target properties
| Protein name | Synaptotagmin-7 |
|---|
| UniProt accession | O43581 |
|---|
| Gene | SYT7 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 403 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (77)
Diseases linked to this target (Open Targets).
- cognitive function measurement · score 0.24
- self reported educational attainment · score 0.19
- intelligence · score 0.11
- myoepithelial tumor · score 0.11
- erythrocyte count · score 0.10
- non-small cell lung carcinoma · score 0.09
- chronic lymphocytic leukemia · score 0.08
- melanoma · score 0.07
- hepatocellular carcinoma · score 0.07
- phosphatidylcholine measurement · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O43581-F1 | alphafold | PREDICTED | 79.00 | — |
Amino-acid sequence (403 residues)
MYRDPEAASP GAPSRDVLLV SAIITVSLSV TVVLCGLCHW CQRKLGKRYK NSLETVGTPD SGRGRSEKKA IKLPAGGKAV NTAPVPGQTP HDESDRRTEP RSSVSDLVNS LTSEMLMLSP GSEEDEAHEG CSRENLGRIQ FSVGYNFQES TLTVKIMKAQ ELPAKDFSGT SDPFVKIYLL PDKKHKLETK VKRKNLNPHW NETFLFEGFP YEKVVQRILY LQVLDYDRFS RNDPIGEVSI PLNKVDLTQM QTFWKDLKPC SDGSGSRGEL LLSLCYNPSA NSIIVNIIKA RNLKAMDIGG TSDPYVKVWL MYKDKRVEKK KTVTMKRNLN PIFNESFAFD IPTEKLRETT IIITVMDKDK LSRNDVIGKI YLSWKSGPGE VKHWKDMIAR PRQPVAQWHQ LKA
Explore Synaptotagmin-7 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets